 |
|
|
| |
Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)ide-naïve patients with chronic hepatitis B (CHB): the BE-LOW study
|
| |
| |
Reported by Jules Levin
AASLD Nov 5-9 2011 SF
Anna S. Lok1, Huy Trinh2, Giampiero Carosi3, Ulus Akarca4, Adrian Gadano5, François Habersetzer6, William Sievert7, David Wong8, Meghan Lovegren9, David Cohen9, Cyril Llamoso9 1. University of Michigan, Ann Arbor, MI, USA; 2. Pacific Health Foundation, 231 O'Connor Drive, San Jose, CA, USA; 3. Institute of Infectious and Tropical Disease, University of Brescia, Brescia, Italy; 4. Department of Gastroenterology, Faculty of Medicine, Ege University, Izmir, Turkey; 5. Seccion Hepatología, Hospital Italiano de Buenos Aires-Argentina, Ciudad de Buenos Aires, Argentina; 6. Service d'Hepato-gastroentérologie, Nouvel Hopital Civil, 1 Place de l'Hopital, Strasbourg, France; 7. Department of Medicine, Monash University, Monash Medical Centre, Melbourne, Australia; 8. Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada; 9. Research and Development, Bristol-Myers Squibb Company, Wallingford, CT, USA
|
| |
|
|
|
|
|
